PDB17 Comparison of Clinical and Economic Outcomes Associated With Dpp4 Inhibitors (DPP4I) Versus Sulfonylurea (SU) in Combination with Metformin (MET) or Pioglitazone (PIO) for the Treatment of Type 2 Diabetes Mellitus (T2DM)

Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.348
https://www.valueinhealthjournal.com/article/S1098-3015(12)02061-X/fulltext
Title : PDB17 Comparison of Clinical and Economic Outcomes Associated With Dpp4 Inhibitors (DPP4I) Versus Sulfonylurea (SU) in Combination with Metformin (MET) or Pioglitazone (PIO) for the Treatment of Type 2 Diabetes Mellitus (T2DM)
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)02061-X&doi=10.1016/j.jval.2012.08.348
First page : A661
Section Title : Diabetes/Endocrine Disorders
Open access? : No
Section Order : 1887
Categories :
Tags :
Regions :
ViH Article Tags :